The board of trustees (the "Board") of NXG Cushing® Midstream Energy Fund (the "Fund") has approved the terms of the issuance of transferable rights ("Rights") to the holders of the Fund's common ...
Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...
10d
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced to the lead optimization s ...
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...
Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...
Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer ...
GlobalData on MSN14d
Boehringer and Circle Pharma link to develop new cancer treatmentBoehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...
Established to produce biosimilars against AbbVie’s (ABBV) Humira in partnership with Sandoz (OTCQX:SDZNY) and Boehringer Ingelheim, Cordavis, and Quallent illustrated PBM’s latest attempts to ...
Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback